Sudden Cardiac Death Clinical Trial
— Post-OvatioOfficial title:
Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study
Verified date | March 2012 |
Source | ELA Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this post-approval study is to confirm the safety and effectiveness of Ovatio DR and VR ICDs
Status | Completed |
Enrollment | 85 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Candidates will come from the investigator's general ICD population who meet any of the accepted indications for an ICD implant according to the "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death" (Zipes et al., JACC Vol. 48, No. 5, Sept. 2006:1064-1108). Exclusion Criteria: - Ventricular tachyarrhythmia that may have transient or reversible causes such as: acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia, sepsis, or unstable ischemic episodes - Incessant tachyarrhythmia - Implanted pacemaker - Primary disorder of bradyarrhythmia or atrial tachyarrhythmia - Of minor age - Pregnant - Participating in another clinical study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Banner Baywood | Mesa | Arizona |
Lead Sponsor | Collaborator |
---|---|
ELA Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percentage of patients free from complications | 6 months | Yes | |
Primary | Shock effectiveness for VT/VF | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02923726 -
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
|
N/A | |
Recruiting |
NCT05175937 -
REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
|
||
Completed |
NCT02026102 -
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
|
N/A | |
Completed |
NCT01262508 -
Development of Algorithms to Predict Hemodynamic Instability
|
N/A | |
Completed |
NCT00998218 -
Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction
|
Phase 3 | |
Completed |
NCT00845286 -
Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial
|
N/A | |
Active, not recruiting |
NCT00562757 -
Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias
|
N/A | |
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT03833843 -
Sudden Cardiac Death in Systemic Right Ventricle
|
||
Completed |
NCT04024865 -
Domperidone and Risk of Serious Cardiac Events in Postpartum Women
|
||
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT05694572 -
Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
|
||
Not yet recruiting |
NCT03622307 -
Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death
|
N/A | |
Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
Recruiting |
NCT02056509 -
The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.
|
N/A | |
Terminated |
NCT01948206 -
Study of Paced QRS Duration as a Marker of Sudden Cardiac Death
|
N/A | |
Completed |
NCT01227785 -
Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study
|
N/A | |
Completed |
NCT00534300 -
Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker
|
Phase 1/Phase 2 | |
Terminated |
NCT00524862 -
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
|
N/A | |
Recruiting |
NCT00181233 -
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
|